In vitro assessment of an engineered tBID-based safety switch system in human T lymphocytes.

ABSTRACT:

Background

Cell therapy as a promising therapeutic modality to treat cancer has been intensively studied for decades. However, the clinical trials have indicated that patients under T cell therapy may develop severe cytokine release syndrome resulting in hospitalization or even death. Furthermore, genetic modifications to promote proliferation and persistence of T cells could result in high numbers of long-lived engineered cells in patients after treatment.

Methods

We incorporated the pro-apoptotic truncated BH3 interacting-domain death agonist (tBID) with the mutant ecDHFR destabilizing domain to form a novel recombinant protein as the major component of an engineered tBID-based safety switch system, which would be unstable and quickly degraded in the absence of trimethopri

SUBMITTER: Lu J 

PROVIDER: S-EPMC8667157 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature